Transcript
Page 1: FDA's Young leaving for new post

FDA's Young leaving for new post After a rocky five-and-a-half-year tenure as head of the Food & Drug Administration, Frank E. Young will leave the agency on Dec. 18 to be­come deputy assistant secretary for health, science, and environment in FDA's parent agency, the Depart­ment of Health & Human Services.

In his new, less visible post, Young will be responsible for de­veloping, assessing, and using new technologies that can improve the nation's health care system. He will report to James O. Mason, assistant HHS secretary for health, who commended him for his role in speeding up FDA's evaluation and approval process of drugs for life-threatening diseases, especially AIDS (acquired immune deficiency syndrome).

Young's move is viewed as later­al by HHS officials. His new posi­tion expands on the one previously held by James Dickson, who was Mason's senior science adviser for environmental affairs.

In the recent past, FDA has been dogged by numerous problems. Among those have been the agency's initial slow response to the AIDS epidemic, corruption and fraud within FDA's generic-drug division, the profusion of misleading health claims on food packages and, most recently, controversy over injuries and deaths from medical devices.

Young: focus of criticism

Some on Capitol Hill and within the pharmaceutical industry believe that Young was made the scapegoat for the generic-drug scandal. Oth­ers say he welcomed the change, that he was tired of the criticisms from FDA's myriad and voluble constituents.

Young is not commenting. But HHS spokesman Ellen Casselberry says, "Mason was concerned about having Dickson's job filled. He asked Young to take the position, and Young said he would."

Rep. Thomas J. Bliley Jr. (R.-Va.), ranking Republican on the House Energy & Commerce Investigation Subcommittee, believes that Young's departure will delay needed reforms at FDA. "He was part of the solu­tion, not part of the problem." Full committee chairman John D. Dingell (D.-Mich.) says Young's intentions were good, "but he was handicapped by the budgets and attitudes of an Administration that let the agency go to seed."

On the other hand, Sidney M. Wolfe, director of Ralph Nader's Public Citizen Health Research Group, tars Young as "by far the worst FDA Commissioner in 18 years. . . . The forced resignation of FDA Commissioner Frank Young can only improve the health of the American public." Wolfe believes that Young pandered to industry and that his "industry-oriented de­cisions have cost hundreds of lives and injuries to many more."

The Pharmaceutical Manufactur­ers Association praises Young for his openness to innovation and for his contributions in the internation­al arena. The group particularly cites Young's championship of the expe­dited review process of drugs for AIDS and other serious diseases.

No successor has been named. HHS's Casselberry says there "may be an announcement before Dec. 18." Unlike Young and his prede­cessors, the next FDA Commission­er will have to be confirmed by the Senate.

One name mentioned as succes­sor is Robert Pinco, a partner in the Washington law firm of Baker & Hostetler.

Lois Ember

ORGANIC INTERMEDIATES FROMSWITZERLAND for

pharmaceuticals • agrochemicals • dyestuffs

flavors • fragrances • photochemicals

Ο Ν-Hydroxy phthalimide

CHa<>

quinazoline- 2,4-dione 6,7-Dimethoxy- CH3° Η

NH2

2,6-Xylidine C H 3 ^ C H 3 and all other isomers

5-Nitroisophthalic acid and derivatives COOH

A 00N ^ COOH

4-Phenylcyclohexanone

COCH3

4-Aminoacetophenone ^H

Custom synthesis against secrecy agreement Our traditional processes: • nitration • catalytic hydrogénation and other reactions

US-Agents: HENLEY CHEMICALS, INC. 50, Chestnut Ridge Road Montvale, NJ 07645 Phone (201)307-0422 FAX (201) 307-0424

R DOTTIKON CH-5605 Dottikon/Switzerland Phone: 057 26 11 55 Telex: 827 923 ssf ch Telefax: 057 24 21 20

CIRCLE 43 ON READER SERVICE CARD November 27, 1989 C&EN 45

Top Related